Foister v. Purdue Pharma, L.P.

295 F. Supp. 2d 693, 2003 U.S. Dist. LEXIS 24274, 2003 WL 23180234
CourtDistrict Court, E.D. Kentucky
DecidedDecember 30, 2003
DocketCIV.A. 6:01-268-DCR
StatusPublished
Cited by15 cases

This text of 295 F. Supp. 2d 693 (Foister v. Purdue Pharma, L.P.) is published on Counsel Stack Legal Research, covering District Court, E.D. Kentucky primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Foister v. Purdue Pharma, L.P., 295 F. Supp. 2d 693, 2003 U.S. Dist. LEXIS 24274, 2003 WL 23180234 (E.D. Ky. 2003).

Opinion

MEMORANDUM OPINION AND ORDER

REEVES, District Judge.

This action involves claims by a number of plaintiffs (both individuals and representatives of estates) who assert that they have been harmed by OxyContin® (“Oxy-Contin”), a pain-relieving drug manufactured by the Purdue defendants (“Purdue”) and marketed by defendant Abbot Laboratories, Inc. (“Abbott”). While the use of OxyContin by some plaintiffs began legitimately, others abused the drug from the outset and in a manner that was clearly contrary to the instructions of their prescribing physicians. And although a variety of factual scenarios are presented, a number of facts are common to all plaintiffs and are dispositive.

This matter is presently before the Court for consideration of the motions for summary judgment filed by defendants Purdue Pharma L.P., The Purdue Frederick Company and Purdue Pharma Inc. [Record Nos. 125, 127, 148, 159, 162, 163] A separate motion for summary judgment has been filed by Abbott. [Record No. 132] In some cases, the plaintiffs’ attorneys attempted to dismiss several claims from this action. Being unsuccessful in this endeavor, they then conceded that summary judgment should be entered against their clients, but ultimately disagreed with the manner of its entry. They argue that the Court should enter judgment without opinion or analysis of the parties’ respective positions. To do more, they claim, would exceed the Court’s jurisdiction. 1 In other instances, the plaintiffs oppose the requested relief.

In opposing these motions, the plaintiffs would have the Court abandon reason and common sense and fall prey to passion and prejudice against the defendants. In essence, the plaintiffs would have the Court ignore their own abuses as well as the warnings and instructions provided by the defendants and by other third party intermediaries. This Court, however, will not accept the plaintiffs’ “victimization” mentality. For the reasons discussed herein, the Court will grant the motions for summary judgment in favor of the defendants and dismiss the claims of all plaintiffs in this action.

I. BACKGROUND

OxyContin is a prescription narcotic intended to help individuals with moderate to severe pain. It contains oxycodone, an opiate analgesic, as well as hydrochloride salt. OxyContin comes in 10, 20, 40, 80, and 160 milligram strength. The 80 mg. and 160 mg. pills are suitable only for opioid tolerant patients. Due to its opioid character, OxyContin is designated as a Schedule II controlled substance by the Food and Drug Administration (“FDA”). Thus, it is illegal to use or sell OxyContin without a valid prescription. 21 U.S.C. § 843(a); KRS § 218A.1415.

Opioids have long been considered useful drugs for pain treatment. P. Tough, The Alchemy of OxyContin, N.Y. Times, *696 July 29, 2001, § 6 (Magazine), at 32. At the same time, however, they have the potential to be highly-addictive. And like any narcotic medication, opioids are subject to abuse if not used as prescribed.

In the 1980’s and 1990’s, a growing movement to liberalize the use of opioids arose in response to the plight of cancer patients beset by extreme pain. Id. In 1994, the Department of Health and Human Services issued clinical guidelines encouraging the use of opioids to treat pain in cancer patients. Id. A year later, the FDA approved the use of OxyContin to treat moderate and severe pain. Id. Much of the drug’s success was due to its time-release function: the pill is designed to release oxycodone in controlled amounts in order to keep the brain from receiving too much oxycodone. This time-release function reduced the likelihood that a patient would experience a euphoric high, as well as reducing the potential for addiction. Id.

Unfortunately, some patients as well as other individuals soon figured out that crushing the tablets would defeat the time-release function. By crushing the pills, these individuals were able to unlock the full narcotic effect of the oxycodone. Id. As word of this procedure spread, abuse of OxyContin proliferated. Abuse of the drug in this manner has been particularly problematic in remote, rural areas such as Eastern Kentucky. Such areas have become a breeding ground for OxyContin abuse because

they’re home to large populations of disabled and chronically ill people who are in need of pain relief; they’re marked by high unemployment and a lack of economic opportunity; they’re remote, far from the network of Interstates and metropolises through which heroin and cocaine travel; and they’re areas where prescription drugs have been abused — • though in much smaller numbers — in the past.

Id.

As discussed below, the plaintiffs used OxyContin at various times for both legitimate and illegitimate purposes. They now complain that they were harmed by their use of OxyContin. All purportedly suffered serious and debilitating side effects; namely, addiction to the drug. 2 Two claim that their relatives were killed by OxyCon-tin. They allege, inter alia, that Purdue did not adequately warn them of the side effects.

A. Michael L. Daniels

Michael Daniels (“Daniels”) is a 35-year old resident of Harlan County with an extensive history of abusing illegal drugs and prescription medications. 3 (Daniels Depo. at 14-22.) At the time of his deposition, Daniels was incarcerated in Tennessee for a felony charge of theft over $1,000 (stolen vehicle). While the result of this charge is unknown and of no consequence in this proceeding, his history of drug use and abuse is relevant.

Daniels abuse of prescription medications began at the age of 16. (Daniels Depo. at 15-16.) His drug history includes use and abuse of marijuana, Percocet, 4 *697 Percodan, 5 Tylox, 6 Roxanol, 7 cocaine, and methamphetamine. (Daniels Depo. at 14-21.) Daniels obtained his first OxyContin pill from a drug dealer in 1998. (Daniels Depo. at 24-26.) He utilized the following procedure to ingest his first pill:

I’d just ... lick the coating off of them, bust them off, buy a bottle of water and pour it in a cap, and I’d just draw up seven units of water and throw on it, take it back to the rig and work it up, and take a piece of cotton off the filter and put it on the needle and filter it, draw it up and hit it.

(Daniels Depo. at 27.) Thus, after modifying the pill he would ingest it intravenously, rather than take it orally. Between 1998 and 1999, Daniels purchased OxyCon-tin on a daily basis and injected it in this manner. (Daniels Depo.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Albert, D. V. Sheeley's Drug Store
2020 Pa. Super. 154 (Superior Court of Pennsylvania, 2020)
Estate of DeMoss ex rel. DeMoss v. Eli Lilly & Co.
234 F. Supp. 3d 873 (W.D. Kentucky, 2017)
Romero v. United States
159 F. Supp. 3d 1275 (D. New Mexico, 2015)
Tug Valley Pharmacy v. All Below
West Virginia Supreme Court, 2015
Tug Valley Pharmacy, LLC v. All Below
773 S.E.2d 627 (West Virginia Supreme Court, 2015)
Prather v. Abbot Laboratories
960 F. Supp. 2d 700 (W.D. Kentucky, 2013)
Schedin v. Ortho-McNeil-Janssen Pharmaceuticals, Inc.
700 F.3d 1161 (Eighth Circuit, 2012)
Souther v. Eli Lilly & Co.
489 F. Supp. 2d 230 (E.D. New York, 2007)
In Re Zyprexa Products Liability Litigation
489 F. Supp. 2d 230 (E.D. New York, 2007)
Smith v. Wyeth Inc.
488 F. Supp. 2d 625 (W.D. Kentucky, 2007)
Price v. Purdue Pharma Co.
920 So. 2d 479 (Mississippi Supreme Court, 2006)
Ernest Price v. The Purdue Pharma Company
Mississippi Supreme Court, 2003

Cite This Page — Counsel Stack

Bluebook (online)
295 F. Supp. 2d 693, 2003 U.S. Dist. LEXIS 24274, 2003 WL 23180234, Counsel Stack Legal Research, https://law.counselstack.com/opinion/foister-v-purdue-pharma-lp-kyed-2003.